Drug intelligence / Profile preview

bifidobacterium animalis subsp. lactis dgcc 420 + lactobacillus acidophilus 74-2 + lactobacillus paracasei lpc-37

Development stage: Unknown
Lead developer: DuPont Nutrition Biosciences
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This probiotic combination consists of three specific bacterial strains: *Bifidobacterium animalis subsp. lactis* DGCC 420 (also known as *B. lactis* 420), *Lactobacillus acidophilus* 74-2, and *Lactobacillus paracasei* Lpc-37. It has been investigated in clinical trials for its ability to modulate the gut microbiota and peripheral immune parameters in both healthy individuals and patients with atopic dermatitis (AD). The mixture acts by transiently colonizing the intestinal tract, reducing the levels of *Clostridium perfringens*, and lowering the genotoxic potential of faecal water, which may provide a protective effect against DNA damage in the colon. In patients with AD, the combination has shown potential in reducing clinical severity (SCORAD) and modulating immune markers, such as decreasing CD4+CD54+ lymphocyte subsets and lowering faecal pH.

Other names: probiotic drinkprobiotic mixprobiotic product

Beyond the preview

Go deeper on bifidobacterium animalis subsp. lactis dgcc 420 + lactobacillus acidophilus 74-2 + lactobacillus paracasei lpc-37.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium animalis subsp. lactis dgcc 420 + lactobacillus acidophilus 74-2 + lactobacillus paracasei lpc-37.

Explore the full profile